Validation and application of an automated multitarget LC-MS/MS method for drugs of abuse testing using exhaled breath as specimen.

Abused drugs Drug testing Exhaled breath Liquid chromatography-mass spectrometry

Journal

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
ISSN: 1873-376X
Titre abrégé: J Chromatogr B Analyt Technol Biomed Life Sci
Pays: Netherlands
ID NLM: 101139554

Informations de publication

Date de publication:
04 May 2024
Historique:
received: 02 03 2024
revised: 26 04 2024
accepted: 27 04 2024
medline: 9 5 2024
pubmed: 9 5 2024
entrez: 8 5 2024
Statut: aheadofprint

Résumé

Aerosol microparticles in exhaled breath carry non-volatile compounds from the deeper parts of the lung. When captured and analyzed, these aerosol microparticles constitute a non-invasive and readily available specimen for drugs of abuse testing. The present study aimed to evaluate a simple breath collection device in a clinical setting. The device divides a breath sample into three parallel "collectors" that can be individually analyzed. Urine was used as the reference specimen, and parallel specimens were collected from 99 patients undergoing methadone maintenance treatment. Methadone was used as the primary validation parameter. A sensitive multi-analyte method using tandem liquid chromatography - mass spectrometry was developed and validated as part of the project. The method was successfully validated for 36 analytes with a limit of detection of 1 pg/collector for most compounds. Based on the validation results tetrahydrocannabinol THC), cannabidiol (CBD), and lysergic acid diethylamide (LSD) are suitable for qualitative analysis, but all other analytes can be quantitively assessed by the method. Methadone was positive in urine in 97 cases and detected in exhaled breath in 98 cases. Median methadone concentration was 64 pg/collector. The methadone metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) was detected in 90 % of the cases but below 10 pg/collector in most. Amphetamine was also present in the urine in 17 cases and in exhaled breath in 16 cases. Several other substances were detected in the exhaled breath and urine samples, but at a lower frequency. This study concluded that the device provides a specimen from exhaled breath, that is useful for drugs of abuse testing. The results show that high analytical sensitivity is needed to achieve good detectability and detection time after intake.

Identifiants

pubmed: 38718698
pii: S1570-0232(24)00150-8
doi: 10.1016/j.jchromb.2024.124142
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

124142

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Hamid Sinapour (H)

Eurofins Clinical Testing AB, Uppsala, Sweden.

Joar Guterstam (J)

Karolinska Institute, Department of Clinical Neuroscience, Stockholm, Sweden.

Susan Grosse (S)

Workplace Drugs Testing Laboratory, Eurofins Forensic Services, London, UK.

Juan Astorga-Wells (J)

Eurofins Clinical Testing AB, Uppsala, Sweden.

Peter Stambeck (P)

Workplace Drugs Testing Laboratory, Eurofins Forensic Services, London, UK.

Matilda Stambeck (M)

Munkplast AB, Uppsala, Sweden.

Jesper Winberg (J)

Munkplast AB, Uppsala, Sweden.

Sigurd Hermansson (S)

Waters Sverige AB, Solna, Sweden.

Olof Beck (O)

Karolinska Institute, Department of Clinical Neuroscience, Stockholm, Sweden. Electronic address: olof.beck@ki.se.

Classifications MeSH